TAFINLAR

Identification of Tafinlar

No description

Google image searchProduct monograph

Active ingredient

dabrafenib (dabrafenib mesylate), 10 MG

DIN: 02540053

Dosage form(s): TABLET FOR SUSPENSION

Route(s) of administration: ORAL

Schedule: Prescription

Company: NOVARTIS PHARMACEUTICALS CANADA INC

Date: 30-NOV-2023

ATC:

• L01 — ANTINEOPLASTIC AGENTS (ATC, ATC/DDD, )
• L01E — PROTEIN KINASE INHIBITORS (ATC, ATC/DDD)
• L01EC — B-Raf serine-threonine kinase (BRAF) inhibitors (ATC, ATC/DDD)
• L01EC02 — DABRAFENIB (ATC/DDD)

Reference brand drug: Tafinlar

External Links for Tafinlar

Search on Google

• Tafinlar side effects
• Tafinlar dosage
• dabrafenib side effects
• dabrafenib dosage

Novartis Pharmaceuticals Canada Inc

Go to Novartis website to see drug product details. Sometimes you can find tafinlar photos and/or monograph. If you are a healthcare professional, you may need to enter your license number.